%A Gambichler,Thilo %A Schmitz,Lutz %D 2018 %J Frontiers in Medicine %C %F %G English %K Ultraviolet,UVA1,UV-A1,Fibrosis,Sclerosis,scleroderma,Lichen sclerosus,Phototherapy %Q %R 10.3389/fmed.2018.00237 %W %L %M %P %7 %8 2018-August-27 %9 Review %# %! UV-A1 for fibrosing conditions %* %< %T Ultraviolet A1 Phototherapy for Fibrosing Conditions %U https://www.frontiersin.org/articles/10.3389/fmed.2018.00237 %V 5 %0 JOURNAL ARTICLE %@ 2296-858X %X In this article we describe efficacy and safety aspects of ultraviolet A1 (UV-A1) phototherapy in fibrosing conditions. UV-A1 is a specific phototherapeutic modality that is defined by a selective spectral range (340–400 nm). UV-A1 includes distinct modes of action qualifying this method for therapy of a variety of conditions, in particular fibrosing skin diseases. Concerning efficacy of UV-A1 phototherapy in fibrosing conditions, the best evidence obtained from randomized controlled trials exists for localized scleroderma. Moreover, fibrosing disorders such as lichen sclerosus and graft-vs.-host disease can be treated successfully by means of UV- A1. Regarding the optimal dosage regimen medium-dose UV-A1 seems to be linked to the best benefit/risk ratio. Possible acute adverse events of UV-A1 phototherapy include erythema and provocation of photodermatoses. Skin ageing and skin cancer formation belong to the chronic adverse events that may occur after long-term UV-A1 phototherapy.